Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT05288894
Recruiting Observational

Repaired Tetralogy of Fallot Italian Registry

NCT05288894 · tracked via the Priya Life Science Italy tracker
Sponsor
Azienda Ospedaliero, Universitaria Ospedali Riuniti
Phase
Observational
Started
2021-03-01
Last updated
2024-04-16

Condition(s) studied

Tetralogy of FallotCardiac Death, SuddenCardiac ArrhythmiaCardiac Event

Investigational drug(s) / intervention(s)

Cardiac magnetic resonance imaging

Cardiac magnetic resonance imaging: A routine cardiac magnetic resonance imaging with biventricular function evaluation, atrial volumes, LGE acquisitions, and pulmonary and aortic assesment.

Study summary

The CMR/CT WG of the Italian pediatric cardiology society set up a multi-center observational clinical database of repaired-TOF evaluated. This registry will enroll prospectively patients evaluated by CMR for clinical indication in most of the CHD Italian centers. Data collection will include surgical history, clinical data, imaging data, and also adverse cardiac events for a period of 6 years.

Eligibility

Sex
ALL
Min age
10 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Patients with Repaired - TOF Exclusion Criteria: * Age \< 10 years * Other associated complex pathology such as MAPCAs, Atrioventricular canal, Ebstein * Incomplete CMR exam

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
CCPC Ancona The Marches Recruiting

More Azienda Ospedaliero, Universitaria Ospedali Riuniti trials in Italy

Rivaroxaban for Intracardiac Thrombosis in the Pediatric Population Recruiting
Efficacy of a Myocardial Panel in the Management and Treatment of Pediatric Myocarditis Recruiting

Other trials for the same condition

CellFX® Nanosecond Pulsed Field Ablation (PFA) 360 Catheter Ablation System for Treatment of Atrial Fibrillation Recruiting
PULSTA Transcatheter Pulmonary Valve Pre-Approval Study Active, not recruiting
Advanced TecHnologies For SuccEssful AblatioN of AF in Clinical Practice Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05288894 on ClinicalTrials.gov ↗ ← All trials in Italy